Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, DeVincenzo JP, Simões EAF, Krilov LR, Forbes ML, Pannaraj PS, Espinosa CM, Welliver RC, Wolkoff LI, Yogev R, Checchia PA, Domachowske JB, Halasa N, McBride SJ, Kumar VR, McLaurin KK, Rizzo CP, Ambrose CS.

Am J Perinatol. 2019 Apr 16. doi: 10.1055/s-0039-1681014. [Epub ahead of print]

2.

Uncovering critical properties of the human respiratory syncytial virus by combining in vitro assays and in silico analyses.

Beauchemin CAA, Kim YI, Yu Q, Ciaramella G, DeVincenzo JP.

PLoS One. 2019 Apr 15;14(4):e0214708. doi: 10.1371/journal.pone.0214708. eCollection 2019.

3.

Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans.

Patel K, Kirkpatrick CM, Nieforth KA, Chanda S, Zhang Q, McClure M, Fry J, Symons JA, Blatt LM, Beigelman L, DeVincenzo JP, Huntjens DR, Smith PF.

J Antimicrob Chemother. 2019 Feb 1;74(2):442-452. doi: 10.1093/jac/dky415.

PMID:
30376079
4.

Comparing molecular quantification of herpes simplex virus (HSV) in cerebrospinal fluid (CSF) with quantitative structural and functional disease severity in patients with HSV encephalitis (HSVE): Implications for improved therapeutic approaches.

Ramirez KA, Choudhri AF, Patel A, Lenny NT, Thompson RE, Berkelhammer Greenberg L, Clanton Watson N, Kocak M, DeVincenzo JP.

J Clin Virol. 2018 Oct;107:29-37. doi: 10.1016/j.jcv.2018.08.005. Epub 2018 Aug 18.

PMID:
30170224
5.

Comparison of antiviral resistance across acute and chronic viral infections.

Mason S, Devincenzo JP, Toovey S, Wu JZ, Whitley RJ.

Antiviral Res. 2018 Oct;158:103-112. doi: 10.1016/j.antiviral.2018.07.020. Epub 2018 Aug 4. Review.

PMID:
30086337
6.

Rat Lungworm Infection Associated with Central Nervous System Disease - Eight U.S. States, January 2011-January 2017.

Liu EW, Schwartz BS, Hysmith ND, DeVincenzo JP, Larson DT, Maves RC, Palazzi DL, Meyer C, Custodio HT, Braza MM, Al Hammoud R, Rao S, Qvarnstrom Y, Yabsley MJ, Bradbury RS, Montgomery SP.

MMWR Morb Mortal Wkly Rep. 2018 Aug 3;67(30):825-828. doi: 10.15585/mmwr.mm6730a4.

7.

Use of real-time semiquantitative PCR data in management of a neonatal intensive care unit adenovirus outbreak.

Hysmith ND, Tanner MR, Arnold SR, Buckingham SC, Patel AR, Dhanireddy R, Comeaux K, Joyner J, Hoehn ME, DeVincenzo JP.

Infect Control Hosp Epidemiol. 2018 Sep;39(9):1074-1079. doi: 10.1017/ice.2018.162. Epub 2018 Jul 18.

PMID:
30019659
8.

Unrecognized prolonged viral replication in the pathogenesis of human RSV infection.

Bagga B, Harrison L, Roddam P, DeVincenzo JP.

J Clin Virol. 2018 Sep;106:1-6. doi: 10.1016/j.jcv.2018.06.014. Epub 2018 Jun 27.

PMID:
30007135
9.

Do asymptomatic respiratory viral infections occur?

Tomlinson RH, Harrison LG, Meals EA, DeVincenzo JP.

J Clin Virol. 2018 May;102:93-94. doi: 10.1016/j.jcv.2018.03.002. Epub 2018 Mar 5. No abstract available.

PMID:
29529485
10.

Angiostrongylus cantonensis Eosinophilic Meningitis in an Infant, Tennessee, USA.

Flerlage T, Qvarnstrom Y, Noh J, Devincenzo JP, Madni A, Bagga B, Hysmith ND.

Emerg Infect Dis. 2017 Oct;23(10):1756-1758. doi: 10.3201/eid2310.170978.

11.

Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants.

Brint ME, Hughes JM, Shah A, Miller CR, Harrison LG, Meals EA, Blanch J, Thompson CR, Cormier SA, DeVincenzo JP.

Pediatr Res. 2017 Nov;82(5):872-880. doi: 10.1038/pr.2017.173. Epub 2017 Aug 9.

12.

Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.

Coates M, Brookes D, Kim YI, Allen H, Fordyce EAF, Meals EA, Colley T, Ciana CL, Parra GF, Sherbukhin V, Stockwell JA, Thomas JC, Hunt SF, Anderson-Dring L, Onions ST, Cass L, Murray PJ, Ito K, Strong P, DeVincenzo JP, Rapeport G.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00737-17. doi: 10.1128/AAC.00737-17. Print 2017 Sep.

13.

Confounding by Indication Limits Conclusions of Study of Palivizumab Effectiveness.

Boyce TG, Yogev R, DeVincenzo JP, Krilov LR.

Pediatrics. 2017 Mar;139(3). pii: e20164247A. doi: 10.1542/peds.2016-4247A. No abstract available.

14.

Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.

Falsey AR, Koval C, DeVincenzo JP, Walsh EE.

Transpl Infect Dis. 2017 Apr;19(2). doi: 10.1111/tid.12657. Epub 2017 Mar 6.

PMID:
28054734
15.

Vaccination strategies against respiratory syncytial virus.

Yamin D, Jones FK, DeVincenzo JP, Gertler S, Kobiler O, Townsend JP, Galvani AP.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13239-13244. Epub 2016 Oct 31.

16.

SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EA, Domachowske JB, Forbes ML, Pannaraj PS, McBride SJ, McLaurin KK, Kumar VR, Ambrose CS.

Am J Perinatol. 2017 Jan;34(1):51-61. doi: 10.1055/s-0036-1584147. Epub 2016 May 27.

17.

Viral Bronchiolitis in Children.

DeVincenzo JP, Krilov LR, Yogev R.

N Engl J Med. 2016 May 5;374(18):1791. doi: 10.1056/NEJMc1601509. No abstract available.

PMID:
27144865
18.

Respiratory Mucosal Proteome Quantification in Human Influenza Infections.

Marion T, Elbahesh H, Thomas PG, DeVincenzo JP, Webby R, Schughart K.

PLoS One. 2016 Apr 18;11(4):e0153674. doi: 10.1371/journal.pone.0153674. eCollection 2016.

19.

ALS-008176 for Respiratory Syncytial Virus Infection.

DeVincenzo JP, McClure MW, Fry J.

N Engl J Med. 2016 Apr 7;374(14):1391-2. doi: 10.1056/NEJMc1516110. No abstract available.

PMID:
27050226
20.

Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.

DeVincenzo JP, Ambrose CS, Makari D, Weiner LB.

Hum Vaccin Immunother. 2016 Apr 2;12(4):971-5. doi: 10.1080/21645515.2015.1115936. Epub 2016 Feb 18.

21.

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.

DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S, Lambkin-Williams R, Smith P, Zhang Q, Beigelman L, Blatt LM, Fry J.

N Engl J Med. 2015 Nov 19;373(21):2048-58. doi: 10.1056/NEJMoa1413275.

22.

Respiratory Syncytial Virus Disease Is Mediated by Age-Variable IL-33.

Saravia J, You D, Shrestha B, Jaligama S, Siefker D, Lee GI, Harding JN, Jones TL, Rovnaghi C, Bagga B, DeVincenzo JP, Cormier SA.

PLoS Pathog. 2015 Oct 16;11(10):e1005217. doi: 10.1371/journal.ppat.1005217. eCollection 2015 Oct.

23.

Viral Specific Factors Contribute to Clinical Respiratory Syncytial Virus Disease Severity Differences in Infants.

Thompson TM, Roddam PL, Harrison LM, Aitken JA, DeVincenzo JP.

Clin Microbiol. 2015 Jun;4(3). pii: 206. Epub 2015 Jun 29.

24.

Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children.

Kim YI, Murphy R, Majumdar S, Harrison LG, Aitken J, DeVincenzo JP.

Pediatr Res. 2015 Oct;78(4):380-8. doi: 10.1038/pr.2015.122. Epub 2015 Jun 24.

25.

Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults.

Bagga B, Cehelsky JE, Vaishnaw A, Wilkinson T, Meyers R, Harrison LM, Roddam PL, Walsh EE, DeVincenzo JP.

J Infect Dis. 2015 Dec 1;212(11):1719-25. doi: 10.1093/infdis/jiv281. Epub 2015 May 14.

PMID:
25977264
26.

Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus.

Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, de Haan CA, Wrammert J, Openshaw PJ, Chiu C; Mechanisms of Severe Acute Influenza Consortium Investigators.

Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9. doi: 10.1164/rccm.201412-2256OC.

27.

Challenges and opportunities in developing respiratory syncytial virus therapeutics.

Simões EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE Jr, Griffiths P, Hayden FG, Hodinka RL, Smyth RL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ.

J Infect Dis. 2015 Mar 15;211 Suppl 1:S1-S20. doi: 10.1093/infdis/jiu828.

28.

Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus.

Kim YI, DeVincenzo JP, Jones BG, Rudraraju R, Harrison L, Meyers R, Cehelsky J, Alvarez R, Hurwitz JL.

PLoS One. 2014 Nov 21;9(11):e113100. doi: 10.1371/journal.pone.0113100. eCollection 2014.

29.

Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis.

Pickles RJ, DeVincenzo JP.

J Pathol. 2015 Jan;235(2):266-76. doi: 10.1002/path.4462. Review.

30.

Oral GS-5806 activity in a respiratory syncytial virus challenge study.

DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, Ramanathan S, O'Riordan T, Lewis SA, Li X, Toback SL, Lin SL, Chien JW.

N Engl J Med. 2014 Aug 21;371(8):711-22. doi: 10.1056/NEJMoa1401184.

31.

Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection.

Cormier SA, Shrestha B, Saravia J, Lee GI, Shen L, DeVincenzo JP, Kim YI, You D.

J Virol. 2014 Aug;88(16):9350-60. doi: 10.1128/JVI.00818-14. Epub 2014 Jun 11.

32.

Multi-center evaluation of the adenovirus R-gene US assay for the detection of adenovirus in respiratory samples.

Manji R, Zheng X, Patel A, Kowerska M, Vossinas M, Drain A, Todd KM, Lenny N, DeVincenzo JP, Ginocchio CC.

J Clin Virol. 2014 Jun;60(2):90-5. doi: 10.1016/j.jcv.2014.03.014. Epub 2014 Mar 29.

PMID:
24768208
33.

RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction.

Liesman RM, Buchholz UJ, Luongo CL, Yang L, Proia AD, DeVincenzo JP, Collins PL, Pickles RJ.

J Clin Invest. 2014 May;124(5):2219-33. doi: 10.1172/JCI72948. Epub 2014 Apr 8.

34.

Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load.

Oshansky CM, Gartland AJ, Wong SS, Jeevan T, Wang D, Roddam PL, Caniza MA, Hertz T, Devincenzo JP, Webby RJ, Thomas PG.

Am J Respir Crit Care Med. 2014 Feb 15;189(4):449-62. doi: 10.1164/rccm.201309-1616OC.

35.

HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection.

Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, Mallal S, Phillips E, James I, Halloran ME, Thomas PG, Corey L.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13492-7. doi: 10.1073/pnas.1221555110. Epub 2013 Jul 22.

36.

Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals.

Bagga B, Woods CW, Veldman TH, Gilbert A, Mann A, Balaratnam G, Lambkin-Williams R, Oxford JS, McClain MT, Wilkinson T, Nicholson BP, Ginsburg GS, Devincenzo JP.

Antivir Ther. 2013;18(6):785-91. doi: 10.3851/IMP2629. Epub 2013 May 28.

PMID:
23714753
37.

Molecular detection and quantification of pertussis and correlation with clinical outcomes in children.

DeVincenzo JP, Guyton C, Rea H, Elmore E, Patel S, Wynn L, Harrison L, El Saleeby CM, Bagga B.

Diagn Microbiol Infect Dis. 2013 May;76(1):10-5. doi: 10.1016/j.diagmicrobio.2012.12.015. Epub 2013 Mar 11.

PMID:
23490009
38.

Complete viral RNA genome sequencing of ultra-low copy samples by sequence-independent amplification.

Malboeuf CM, Yang X, Charlebois P, Qu J, Berlin AM, Casali M, Pesko KN, Boutwell CL, DeVincenzo JP, Ebel GD, Allen TM, Zody MC, Henn MR, Levin JZ.

Nucleic Acids Res. 2013 Jan 7;41(1):e13. doi: 10.1093/nar/gks794. Epub 2012 Sep 8.

39.

Assessing Modeled CO(2) Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants.

Mundt C, Sventitskiy A, Cehelsky JE, Patters AB, Tservistas M, Hahn MC, Juhl G, Devincenzo JP.

ISRN Pediatr. 2012;2012:721295. doi: 10.5402/2012/721295. Epub 2012 Jun 26.

40.

The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses.

DeVincenzo JP.

Antivir Ther. 2012;17(1 Pt B):213-25. doi: 10.3851/IMP2064. Epub 2012 Feb 3. Review.

PMID:
22311654
41.

Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children.

El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP.

J Infect Dis. 2011 Oct 1;204(7):996-1002. doi: 10.1093/infdis/jir494.

42.

Respiratory syncytial virus load and disease severity in the community.

El Saleeby CM, Devincenzo JP.

J Med Virol. 2011 May;83(5):904-5. doi: 10.1002/jmv.22039. No abstract available.

PMID:
21412798
43.

Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R, Dorsett P, Alvarez R, Lambkin-Williams R.

Am J Respir Crit Care Med. 2010 Nov 15;182(10):1305-14. doi: 10.1164/rccm.201002-0221OC. Epub 2010 Jul 9.

44.

Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population.

El Saleeby CM, Li R, Somes GW, Dahmer MK, Quasney MW, DeVincenzo JP.

J Pediatr. 2010 Mar;156(3):409-14. doi: 10.1016/j.jpeds.2009.09.043. Epub 2009 Nov 14.

PMID:
19914637
45.

Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.

DeVincenzo JP.

Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013. Epub 2009 Oct 14.

PMID:
19833462
46.

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.

Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA.

Pediatr Infect Dis J. 2009 Sep;28(9):835-7. doi: 10.1097/INF.0b013e3181a165e4.

PMID:
19636278
47.

RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.

Alvarez R, Elbashir S, Borland T, Toudjarska I, Hadwiger P, John M, Roehl I, Morskaya SS, Martinello R, Kahn J, Van Ranst M, Tripp RA, DeVincenzo JP, Pandey R, Maier M, Nechev L, Manoharan M, Kotelianski V, Meyers R.

Antimicrob Agents Chemother. 2009 Sep;53(9):3952-62. doi: 10.1128/AAC.00014-09. Epub 2009 Jun 8.

48.

Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial.

Somers CC, Ahmad N, Mejias A, Buckingham SC, Carubelli C, Katz K, Leos N, Gomez AM, DeVincenzo JP, Ramilo O, Jafri HS.

Pediatr Allergy Immunol. 2009 Aug;20(5):477-85. doi: 10.1111/j.1399-3038.2009.00852.x. Epub 2009 Apr 24.

PMID:
19397752
49.

2007 International Congress on Respiratory Viruses. Introduction.

DeVincenzo JP, de Swart RL, Osterhaus AD.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S53. doi: 10.1097/INF.0b013e31816d69bd. No abstract available.

PMID:
18820577
50.

RNA interference strategies as therapy for respiratory viral infections.

DeVincenzo JP.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S118-22. doi: 10.1097/INF.0b013e318168b759.

PMID:
18820571

Supplemental Content

Loading ...
Support Center